fda tirzepatide compounding warning 2024 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our March 10, 2025: Patients transitioning

Mitochondrial DNA (mtDNA), which encodes 37 genes essential for protein synthesis and energy production, is particularly susceptible to oxidative damage

The combination of semaglutide and glycine is not approved by the FDA

SEE WHICH OPTION IS RIGHT FOR YOU If youre considering tirzepatide and have hypothyroidism, here are the steps to take: Tirzepatide and hypothyroidism can safely coexist for most patients

Patients with heart failure, particularly those at a more advanced stage, are vulnerable to a range of factors that may increase their risk for cardiovascular-related hospitalizations

The dose of the medication is increased if clinically indicated, highlighting the importance of enrolment in a medically supervised programme

Every patient is different